Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson’s disease

Chun-Hyung Kim,Baek-Soo Han,Jisook Moon,Deog-Joong Kim,Joon Shin,Sreekanth Rajan,Quoc Toan Nguyen,Mijin Sohn,Won-Gon Kim,Minjoon Han,Inhye Jeong,Kyoung-Shim Kim,Eun-Hye Lee,Yupeng Tu,Jacqueline L. Naffin-Olivos,Chang-Hwan Park,Dagmar Ringe,Ho Sup Yoon,Gregory A. Petsko,Kwang-Soo Kim

DOI: https://doi.org/10.1073/pnas.1509742112

IF: 11.1

2015-06-29

Proceedings of the National Academy of Sciences

Abstract:Significance Parkinson’s disease (PD) is the most prevalent movement disorder with no available treatments that can stop or slow down the disease progress. Although the orphan nuclear receptor Nurr1 is a promising target for PD, it is thought to be a ligand-independent transcription factor and, so far, no small molecule has been identified that can bind to its ligand binding domain. Here, we established high throughput cell-based assays and successfully identified three Nurr1 agonists among FDA-approved drugs, all sharing an identical chemical scaffold. Remarkably, these compounds not only directly bind to Nurr1 but also ameliorate behavioral defects in a rodent model of PD. Thus, our study shows that Nurr1 could serve as a valid drug target for neuroprotective therapeutics of PD.